SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $21,010.64 in Stock

Key Points

• Insider sale: Chief or insider Zhenyu Xu executed a pre-arranged Rule 10b5-1 sale of 4,414 shares on April 13 for $21,010.64 to cover tax withholding, reducing his stake by 0.69% while still owning 632,096 shares (~$3.01M).
• Weak recent results but stable trading: SOPH shares rose 2.3% to $4.96 and have a market cap of ~$339.7M, but the company reported a quarterly EPS of -$0.28 (missed estimates), a -44.2% net margin, and $21.71M in revenue.
• Mixed analyst view: Analyst coverage is split (two Buys, one Sell) producing a consensus "Hold" and an average price target of $7.00, with institutional investors owning about 31.6% of the stock.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,414 shares of the stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $4.76, for a total transaction of $21,010.64. Following the transaction, the insider owned 632,096 shares in the company, valued at approximately $3,008,776.96. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Zhenyu Xu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Stock Up 2.3%

Shares of NASDAQ:SOPH traded up $0.11 during trading on Tuesday, reaching $4.96. The stock had a trading volume of 148,768 shares, compared to its average volume of 183,135. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The company has a market capitalization of $339.71 million, a P/E ratio of -9.73 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm's 50-day simple moving average is $4.74 and its 200 day simple moving average is $4.71.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The firm had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. As a group, research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim lifted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Finally, BTIG Research reiterated a "buy" rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $7.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors have recently bought and sold shares of the stock. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS in the 3rd quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter worth approximately $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.